CATALYSTBenzinga • 2d ago
Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Raises Price Target to $13Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and raises the price target from $10 to $13.
Why ACRS Stock advanced +0.76% Today — RQD Quant Desk Flash
$3.99 +0.76% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.99
Aclaris Therapeutics Inc. (ACRS) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $587.3M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.99 (-0.05%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACRS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY ACRS SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (39% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (32% of score)
FRED Regime × Technicals: 42% of 52W Range • RSI-14 at 45.5 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$3.83-14.4% Next Q
23
Q2 (-2Q)Grade E$3.28+14.3% Next Q
26
Q3 (-1Q)Grade E$3.75+6.4% Next Q
28
CurrentGrade E$3.99-9.4% Hist 90D α
31
Trajectory: E (23) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ACRS Turnaround Squeeze
While ACRS currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.88) and Max Pain ($4.19) forces dealer call-delta covering toward $6.93.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACRS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ACRS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ACRS Stock advanced +0.76% Today — RQD Quant Desk Flash
Aclaris Therapeutics Inc. (ACRS) advanced +0.76% to $3.99, trading at 42% of its 52-week range ($2.1 – $6.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 42% of its 52-week range ($2.1 – $6.6) with RSI-14 at 45.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.99 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 73.3% gross margin and $0 annual free cash flow.
Live ACRS Headlines & Catalysts
MARKET WIRESeekingAlpha • 3d ago
Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma - Slideshow2026-10-29. The following slide deck was published by Aclaris Therapeutics, Inc.
MARKET WIREBenzinga • 4d ago
Wedbush Maintains Outperform on Aclaris Therapeutics, Lowers Price Target to $8Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and lowers the price target from $10 to $8.
MARKET WIREBenzinga • 4d ago
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price TargetHC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.
MARKET WIREYahoo • 4d ago
Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1bAclaris Therapeutics (NASDAQ:ACRS) reported Phase 1b proof-of-concept results for ATI-052, its bispecific antibody designed to inhibit thymic stromal lymphopoietin (TSLP) and IL-4 receptor alpha, in small studies of atop
MARKET WIREYahoo • 5d ago
Aclaris Therapeutics Reports Positive Phase 1b ATI-052 Trial Results, Prices $50 Million OfferingAclaris Therapeutics (ACRS) said Tuesday the phase 1b proof-of-concept trials of its anti-TSLP/IL-4R
MARKET WIREBenzinga • 5d ago
Aclaris Says Early Data Validates Dual-Target Approach for Eczema, Asthma DrugAclaris Therapeutics announces positive Phase 1b trial data for ATI-052 in eczema and asthma alongside a $50 million public financing round.
MARKET WIREYahoo • 5d ago
Aclaris Reports Positive Asthma, Eczema Drug Trial Results — So, Why Is ACRS Stock Down Nearly 8%?Aclaris announced plans to sell about 7.8 million shares and pre-funded warrants at $3.50 each, a 7.65% discount to Monday’s closing price.
MARKET WIREYahoo • 5d ago
Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded WarrantsWAYNE, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today a
MARKET WIREYahoo • 5d ago
Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma- Results Demonstrated Breadth and Rapidity of Response to ATI-052 in Heterogeneous Patient Populations; Pharmacodynamic Results Demonstrated Potential for Additivity/Synergy of Targeting TSLP and IL-4Rα - - Rapid and Du
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACRS)
- ✓Walkthrough of ACRS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ACRS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -8.06%📐 HORIZONTAL RANGE
2026-10-30O $4.00H $4.07L $3.87C $3.99VOL 1.88M
RES: $7.99SUP: $3.01SMA50: $4.88SMA200: $4.53
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ACRS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -58.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ACRS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ACRS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ACRS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACRS)
Health Care Rank #914 of 1016
⚔️ CLYM vs ACRS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ACRS vs. CLYM, CRMD, NGNE, IRWD)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Aclaris Therapeutics Inc. (ACRS) ranks #914 by composite RQD confidence (31/100, grade E) and #424 by equity capitalization ($587.3M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with ACRS at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ACRS
ACTIVE
Aclaris Therapeutics Inc. | E | 31/100 | — | 73.3% | -35.0% | +0.76% | $587.3M | Benchmark Subject |
| CLYM Climb Bio Inc. | D- | 38/100 | — | — | -35.0% | +2.08% | $593.3M | /clym-vs-acrs → |
| CRMD CorMedix Inc. | C | 62/100 | 3.7x | 88.5% | 45.5% | -6.83% | $595.5M | /crmd-vs-acrs → |
| NGNE Neurogene Inc. | D- | 36/100 | — | — | -35.0% | -5.26% | $576.7M | /ngne-vs-acrs → |
| IRWD Ironwood Pharmaceuticals Inc. (Class A) | C+ | 69/100 | 24.9x | — | 85.0% | +0.28% | $598.2M | /irwd-vs-acrs → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001557746In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aclaris Therapeutics Inc. (ACRS) reported GAAP revenue of $7.8M (-58.2% vs. FY2024 revenue of $18.7M , and -75.0% cumulative change since FY2023) , GAAP net income of -$64.9M, operating cash flow of -$47.1M, and free cash flow of -$47.2M (-133.8% YoY). On the balance sheet, ACRS closed FY2025 with $160.5M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $7.8M | -$64.9M | -$47.1M | -$47.2M | $160.5M | — |
| FY2024 (FY) | 2024-12-31 | $18.7M | -$132.1M | -$20.1M | -$20.2M | $220.3M | — |
| FY2023 (FY) | 2023-12-31 | $31.2M | -$88.5M | -$78.3M | -$78.3M | — | — |
3. ACRS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ACRS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Aclaris Therapeutics Inc. (NASDAQ: ACRS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.99 (+0.76% 1D, market cap $587.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ACRS ranks #914 in composite RQD confidence.
How does ACRS compare to CLYM and CRMD in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACRS carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 73.3%, and ROIC of -35.0%. By comparison, CLYM (Climb Bio Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $593.3M) and CRMD (CorMedix Inc.) posts a C grade (62/100 RQD, P/E 3.7x, ROIC 45.5%, cap $595.5M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while IRWD leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ACRS?
Per ACRS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001557746), Aclaris Therapeutics Inc. generated $7.8M in revenue (-58.2% YoY), -$64.9M in net income, and -$47.2M in free cash flow against $160.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ACRS trading relative to its 50-day, 200-day, and 52-week technical levels?
ACRS last traded at $3.99 (+0.76% on volume of 1,458,849 shares), positioning the stock -18.24% below its 50-day simple moving average ($4.88) and -11.92% below its 200-day simple moving average ($4.53). Across its 52-week range of $2.10 to $6.60, ACRS sits at the 42.0% percentile with a 14-day RSI of 45.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.49 to $4.49).
ACRS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ACRS stock moving today?
Why ACRS Stock advanced +0.76% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.